As of today (2024-04-25), IGC Pharma's share price is $0.439. IGC Pharma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.12. Hence, IGC Pharma's Price to Tangible Book Ratio of today is 3.57.
The historical rank and industry rank for IGC Pharma's Price-to-Tangible-Book or its related term are showing as below:
IGC'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.25 Med: 1.31 Max: 17.97
Current: 3.66
During the past 13 years, IGC Pharma's highest Price to Tangible Book Ratio was 17.97. The lowest was 0.25. And the median was 1.31.
IGC's Price-to-Tangible-Book is ranked worse than 62.3% of 1220
companies
in the Biotechnology industry
Industry Median: 2.67
vs IGC: 3.66
A closely related ratio is called PB Ratio. As of today, IGC Pharma's share price is $0.439. IGC Pharma's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.14. Hence, IGC Pharma's P/B Ratio of today is 3.09.
IGC Pharma Price-to-Tangible-Book Historical Data
The historical data trend for IGC Pharma's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IGC Pharma's Price-to-Tangible-Book
For the Biotechnology subindustry, IGC Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Price-to-Tangible-Book falls into.
IGC Pharma Price-to-Tangible-Book Calculation
IGC Pharma's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
IGC Pharma Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGC has been successfully added to your 